Pharmacological experiments demonstrate that toad (Bufo marinus) atrial beta-adrenoceptors are not identical with mammalian beta2- or beta1-adrenoceptors

Chronotropic responses to symphathomimetic amines of isolated atrial preparations from toads ($\text{Bufo marinus}$) were mediated by β-adrenoceptors since isoprenaline was more potent than adrenaline and noradrenaline, and propranolol was a potent antagonist (pA₂, adrenaline as agonist = 9.33). The β-adrenoceptors had some of the characteristics of mammalian β₂-adrenoceptors in that (i) adrenaline was more potent than noradrenaline and (ii) the pA₂ values of two selective β-adrenoceptor antagonists, atenolol (pA₂ = 5.84) and α-methylpropranolol (pA₂ = 8.42), were close to the values reported on β₂-adrenoceptors in mammalian tissues. However, the relative potencies of adrenaline, isoprenaline, noradrenaline, rimiterol, salbutamol and fenoterol (1 : 45.8 : 0.07 : 3.3 : 1.05 : 0.32) did not correspond to the relative potencies reported for these agonist on mammalian tissues which contain predominantly β₂-adrenoceptors. Also the pA₂ value for the β₂-selective antagonist, ICI 118,551 (7.89, adrenaline as agonist) was lower than its reported pA₂ on β₂-adrenoceptors in mammalian tissues. There was no evidence that the response was mediated by both β₁-andβ₂-adrenoceptors since Schild plots for ICI 118,551 using three agonists of differing selectivity (adrenaline, rimiterol and noradrenaline) weer superimposed. It is concluded that, although toad atrial β-adrenoceptors have several characteristics in common with β₂-adrenoceptors in mammalian tissues, these amphibian β-adrenoceptors are not identical with mammalian β₂-adrenoceptors.     

The pharmacology of the isolated foregut of the locust Schistocerca gregaria—II. characterization of a 5-HT2-like receptor

1. 5-HT (10⁻⁸−5 × 10⁻⁶ M) relaxed isolated locust foreguts.2. The effects of 5-HT were mimicked by 5,6-DHT, 5-MeOT, tryptamine, 5-MeT, MK212 and methysergide while 5-hydroxyindole, 5-hydroxyindole acetic acid, 5-hydroxytryptophol, NN-DMT, 8-OH DPAT and RU 24969 were without effect.3. Ketanserin (pA₂ = 5.65) was a competitive antagonist of the effects of 5-HT, MK212 and methysergide.4. Mianserin (pA₂ = 6.3) was also a competititve antagonist of 5-HT but ICS 205-930 had no antagonistic effect on 5-HT-induced relaxation.5. It is concluded that 5-HT relaxes the locust foregut by interacting with 5-HT₂-like receptors.     

Threshold and Receptor Reserve in the Action of Neurohypophyseal Peptides : A study of synergists and antagonists of the hydroosmotic response of the toad urinary bladder

The interrelationship of several physiological receptors which influence the hydroosmotic response of the toad urinary bladder was studied employing neurohypophyseal peptides, prostaglandin E₁, theophylline, and cyclic nucleotides. The binding property of agonists (pD₂), synergists (pS₂), competitive antagonists (pA₂), and noncompetitive antagonists (pD₂') was determined after a suitable methodology had been developed. A series of neurohypophyseal peptides was examined in detail for their catalytic activity. It was found that the replacement of the hydroxy radical of the tyrosine residue in oxytocin by a methoxy and then by an ethoxy radical led to a progressive decline in the catalytic activity of the hormone—corresponding to a change from agonist to partial agonist to competitive antagonist. [4-Leucine]-mesotocin behaved as a competitive antagonist of oxytocin. Prostaglandin E₁ (PGE₁) was found to be a noncompetitive inhibitor of neurohypophyseal peptides and theophylline; whereas the maximal hydroosmotic response of the bladder to [2-O-methyltyrosine]-oxytocin and theophylline was greatly depressed by PGE₁, the response to saturating concentrations of oxytocin was only slightly diminished—a finding which reveals a "receptor reserve" for oxytocin. Saturating concentrations of [2-O-ethyltyrosine]-oxytocin, inactive per se, potentiate theophylline—disclosing a "threshold phenomenon" for the mediation of neurohypophyseal hormone action. It is concluded that neurohypophyseal peptides are capable of producing graded effects on adenyl cyclase both below and above the range of enzyme activity which evokes graded changes in membrane permeability.     

Cholinergic Receptors in the Human vas Deferens

Abstract

This study represents the first investigation demonstrating the contractile response to exogenous acetylcholine (ACh) in the isolated human vas deferens. Pharmacological characterization of cholinergic receptors was achieved using selective antagonists to define receptor subtypes. In the HVD the effect of exogenous ACh is revealed as a dose-dependent sudden increase in the basal tension of the vasa. The ACh receptors of the HVD were competitively antagonized by atropine (ATR) with a high pA₂ value (8.78). The main finding of this study is the presence of cholinergic receptors of the pharmacologically defined M₂-ACh subtype in the isolated HVD, according to the pA₂ values obtained with pirenzepine (PRZ) 7.39, AF-DX 116 (AF) 5.92 and 4-DAMP 5.65, M₁-ACh, _M2-ACh and M₃-ACh selective antagonists, respectively. Prazosin (PZ), a selective α₁-adrenergic antagonist, displayed a similar competitive antagonism for the contractile response evoked both by ACh (pA₂ = 8.69) and NE (pA₂ = 8.58) in the HVD. The antagonism exerted by PZ on the ACh-induced contractile response of the HVD, suggests that ACh probably acts at a presynaptic level stimulating the release of NE from an adrenergic neuron. According to these findings, the receptor involved in this action, located in the proximity of the nerve terminals, seems to be of the M₂-ACh subtype.     

Evidence that ICI 118, 551 is a potent, highly Beta 2-selective adrenoceptor antagonist and can be used to characterize Beta-adrenoceptor populations in tissues

pA₂ values for a new ß-adrenoceptor antagonist, ICI 118, 551 (erythro-DL-1(7-methylindan-4-yloxy)-3-isopropylaminobutan-2-o1), have been obtained on intrinsic tone tracheal chain preparations and on spontaneously beating atrial preparations from guinea-pigs. Two different agonists, fenoterol (ß₂-selective) and noradrenaline (ß₁-selective) were used. The slopes of the Schild plots were not significantly different from 1.0. The antagonist was very potent (pA₂ on trachea, fenoterol as agonist, was 8.69) and also highly ß₂-selective (pA₂ on atria, noradrenaline as agonist, was only 6.96). On guinea-pig trachea (which contains ß₁- and ß₂-adrenoceptors) the potency was 44 times higher when fenoterol was the agonist than when noradrenaline was the agonist. On guinea-pig atria (which contains only ß₁-adrenoceptors) the pA₂ value was the same whichever agonist was used. Thus ICI 118, 551 has been shown to be potent and the most ß₂-selective antagonist so far studied in our laboratory. In experiments carried out with selective agonists ICI 118, 551 distinguished clearly between tissues with a mixed ß-adrenoceptor population (different pA₂ values) and those with a homogeneous population (single pA₂ value). Therefore, ICI 118, 551 is a valuable addition to the group of ß₂-selective adrenoceptor antagonists.     

Synthesis and pharmacological investigation of azaphthalazinone human histamine H1 receptor antagonists

5-Aza, 6-aza, 7-aza and 8-aza-phthalazinone, and 5,8-diazaphthalazinone templates were synthesised by stereoselective routes starting from the appropriate pyridine/pyrazine dicarboxylic acids by activation with CDI, reaction with 4-chlorophenyl acetate ester enolate to give a β?ketoester, which was hydrolysed, and decarboxylated. The resulting ketone was condensed with hydrazine to form the azaphthalazinone core. The azaphthalazinone cores were alkylated with N-Boc-D-prolinol at N-2 by Mitsunobu reaction, de-protected, and then alkylated at the pyrrolidine nitrogen to provide the target H₁ receptor antagonists. All four mono-azaphthalazinone series had higher affinity (pK_i) for the human H₁ receptor than azelastine, but were not as potent as the parent non-aza phthalazinone. The 5,8-diazaphthalazinone was equipotent with azelastine. The least potent series were the 7-azaphthalazinones, whereas the 5-azaphthalazinones were the most lipophilic. The more hydrophilic series were the 8-aza series. Replacement of the N-methyl substituent on the pyrrolidine with the n-butyl group caused an increase in potency (pA₂) and a corresponding increase in lipophilicity. Introduction of a β-ether oxygen in the n-butyl analogues (2-methoxyethyl group) decreased the H₁ pA₂ slightly, and increased the selectivity against hERG. The duration of action in vitro was longer in the 6-azaphthalazinone series. The more potent and selective 6-azaphthalazinone core was used to append an H₃ receptor antagonist fragment, and to convert the series into the long acting single-ligand, dual H₁ H₃ receptor antagonist 44. The pharmacological profile of 44 was very similar to our intranasal clinical candidate 1.     

Hydraulic conductance,stomatal conductance,and maximal photosynthetic rate in bean leaves

A positive correlation was found between steady state values of hydraulic (L _pA) and stomatal conductance (g _s) of French bean leaves: both were lower in the dark than in the light and lower in water-deficient plants than in the well-watered ones. The relative rate of stomatal opening after a pressure rise in the xylem was also positively related to L _pA. The L _pA and g _s were both related to the maximal photosynthetic rate at saturating CO2 concentrations.     

Similar atypical β-adrenergic receptors mediate in vitro rat adipocyte lipolysis and colonic motility inhibition

We investigated the putative common nature of the rat atypical β-adrenoceptors mediating white adipocyte lipolysis and proximal colon motility inhibition, using the non-selective antagonist alphenolol and agonist isoprenaline and the selective agonists SR 58611A and BRL 37344. Results in either isolated intestinal and fat tissues were consistent with: isoprenaline acting through both typical (β₁, β₂) and atypical β-adrenoceptors; SR 58611A and BRL 37344 acting solely through the latter. The identical pA₂ values obtained with alprenolol, irrespective of the tissue and the selective agonist (SR 58611A or BRL 37344) used, support the high functional homology of the atypical β-adrenoceptors in rat colon and adipocytes.     

Effect of a new CCK-A receptor antagonist,dexloxiglumide, on the exocrine pancreas in the rat

The effect of dexloxiglumide, a new potent cholecystokinin (CCK) antagonist, on pancreatic enzyme secretion and growth was studied in the rat. Pancreatic exocrine secretion was studied both in vitro (isolated and perfused pancreatic segments) and in vivo (anaesthetized animals with cannulation of the common bile duct) whereas the trophic effect was investigated after short-term (7 days) administration of the CCK-agonist, caerulein, or camostate (a potent trypsin inhibitor), with or without dexloxiglumide. CCK-8 stimulated amylase release from in vitro pancreatic segments in a concentration-dependent manner. Dexloxiglumide displaced the concentration response curves to CCK-8 to the right without affecting the maximum response, suggesting a competitive antagonism. The Schild plot analysis of data gave a straight line with a slope (0.90±0.36) not significantly different from unity. The calculated pA₂ for dexloxiglumide was 6.41 ± 0.38. In vivo experiments confirmed results from in vitro studies since intravenous dexloxiglumide reduced pancreatic exocrine secretion induced by submaximal CCK-8 stimulation (0.5 nmol/kg/h) in a dose-dependent manner, the ID₅₀ being 0.64 mg/kg. Both exogenous and endogenous (released by camostate) CCK increased the weight of the pancreas, the total pancreatic protein and DNA, trypsin and amylase content. Dexloxiglumide (25 mg/kg), administered together with caerulein (1 μg/kg), reduced the peptide-induced increase in pancreatic weight, protein and enzyme content. Similarly, when dexloxiglumide was given together with camostate (200 mg/kg), all the observed changes were reduced by concomitant administration of the antagonist. These results demonstrate the ability of dexloxiglumide to antagonize the effects of CCK on pancreatic secretion and growth, suggesting that this compound is a potent and selective antagonist of CCK-A-receptors in the pancreas.     

Evidence for multiple leukotriene D4 receptors in smooth muscle

Using pure leukotriene D₄ (LTD₄) as the agonist, we determined the dissociation constants, K_B and pA₂ values, for the selective leukotriene antagonist FPL 55712 on guinea pig ileum, trachea, and parenchyma. Responses of the 3 tissues to LTD₄ were competitively antagonized by FPL 55712. K_B and pA₂ values were similar for trachea and parenchyma. However, these values differed from those obtained in ileum. We propose the existence of multiple LTD₄ receptors, with those in lung differing from LTD₄ receptors in ileum.     

Interaction of BW A868C, a prostanoid DP-receptor antagonist, with two receptor subtypes in the rabbit isolated saphenous vein

In isolated rings of rabbit saphenous vein (RbSV) pre-contracted with 40 mM KCl, Prostaglandin E₂ (PGE₂), BW245C (a DP-receptor agonist) and PGD₂ caused concentration-dependent relaxations with mean potencies (EC₅₀) of 0.5, 38 and 114 nM respectively.The DP-receptor antagonist, BW A868C, antagonized BW245C concentration-effect ( ) curves, although the corresponding Schild plot had a slope less than unity and displayed a clear inflection. Analysis of the data yielded two pK_B estimates of 8.5 and 4.9, the higher estimate being consistent with antagonism at DP-receptors. The pA₂ estimate of 5.1 obtained for BW A868C against PGE₂ was not statistically different to the lower pK_B of 4.9 obtained against BW245C, and is probably indicative of antagonism at the EP₄-receptor. PGD₂ mediated responses were also antagonized by BW A868C, however the resultant curves were ‘bell shaped’ in nature. The weak EP₄-receptor antagonist AH23848B, also antagonized BW245C and PGD₂ responses, yielding pA₂ estimates of 5.6 and 5.5 respectively.These results suggest that in the RbSV, BW245C and PGD₂ are nonselective agonists mediating relaxations through DP- and EP₄-receptors. BW A868C also displayed an affinity for DP-receptors in this preparation, in addition to a second receptor subtype, presumably the EP₄-receptor.     

Influence of sarmesin on the cardiac and vascular actions of angiotensin II

Summary The angiotensin II (ANG II) receptor blocker properties of sarmesin and its influence on the homotropic cooperativity of ANG II receptors were studied in two experimental models: isolated rabbit aorta and isolated rabbit atria. The results show that: (i) sarmesin is a specific competitive antagonist of ANG II receptors, with high affinity (pA₂=8.93 in the isolated aorta and 8.66 in the isolated atria); and (ii) the slope of the concentration-response curves to ANG II and the Hill coefficient increased in the presence of sarmesin, the latter suggesting an enhancement of the positive homotropic cooperativity of ANG II receptors. These results may be explained overall by the reciprocal negative modulation of receptor affinity between sarmesin and ANG II, due, possibly, to opposite effects on the binding of G-proteins to ANG II receptors.     

A comparison of Xenopus laevis oocyte and embryo mRNA

Total RNA, extracted from mature oocytes and tadpoles of Xenopus laevis, was used as a template for in vitro protein synthesis. The oocyte RNA is markedly deficient in abundant mRNA species by comparison to tadpole RNA or other somatic RNAs, in agreement with previous experiments using RNA-cDNA hybridization analysis (S. Perlman and M. Rosbash, 1978, Develop. Biol.63, 197–212). Oocyte pA⁺ RNA is also larger than tadpole pA⁺ RNA or other somatic pA⁺ populations. The larger oocyte pA⁺ RNA and smaller oocyte pA⁺ RNA are equally good templates for in vitro protein synthesis, which implies that much, and perhaps all, of the large oocyte pA⁺ RNA is bona fide mRNA. We suggest that the relatively large size of the oocyte pA⁺ RNA population is due, at least in part, to the relative lack of abundant mRNA species in the population. This suggestion follows from the observation of 0. Meyuhas and R. P. Perry (1979, Cell16, 139–148) that L-cell-abundant mRNAs are preferentially small and rare mRNAs preferentially large. Most of the oocyte pA⁺ sequences are also present in tadpoles and are still adenylated at this stage. Oocyte proteins synthesized in vivo do not appear deficient in abundant proteins, suggesting that a translational control mechanism operates to select certain pA⁺ RNAs at higher frequencies than others.     

In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB1 receptor antagonist for the management of obesity

Cannabinoid CB₁ receptor antagonists exhibit pharmacologic properties favorable for the treatment of metabolic disease. CP-945,598 (1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylamino piperidine-4-carboxylic acid amide hydrochloride) is a recently discovered selective, high affinity, competitive CB₁ receptor antagonist that inhibits both basal and cannabinoid agonist-mediated CB₁ receptor signaling in vitro and in vivo. CP-945,598 exhibits sub-nanomolar potency at human CB₁ receptors in both binding (K_i = 0.7 nM) and functional assays (K_i = 0.2 nM). The compound has low affinity (K_i = 7600 nM) for human CB₂ receptors. In vivo, CP-945,598 reverses four cannabinoid agonist-mediated CNS-driven responses (hypo-locomotion, hypothermia, analgesia, and catalepsy) to a synthetic cannabinoid receptor agonist. CP-945,598 exhibits dose and concentration-dependent anorectic activity in two models of acute food intake in rodents, fast-induced re-feeding and spontaneous, nocturnal feeding. CP-945,598 also acutely stimulates energy expenditure in rats and decreases the respiratory quotient indicating a metabolic switch to increased fat oxidation. CP-945,598 at 10 mg/kg promoted a 9%, vehicle adjusted weight loss in a 10 day weight loss study in diet-induced obese mice. Concentration/effect relationships combined with ex vivo brain CB₁ receptor occupancy data were used to evaluate efficacy in behavioral, food intake, and energy expenditure studies. Together, these in vitro, ex vivo, and in vivo data indicate that CP-945,598 is a novel CB₁ receptor competitive antagonist that may further our understanding of the endocannabinoid system.     

An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2,3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin

We have investigated the effects of mono-substitutions with the conformationally restricted amino acid, 1,2,3,4 tetrahydroisoquinoline-3-carboxylic acid (Tic) at position 3 in arginine vasopressin (AVP), at positions 2, 3 and 7 in potent non-selective cyclic AVP V₂/V_1a antagonists, in potent and selective cyclic and linear AVP V_1a antagonists, in a potent and selective oxytocin antagonist and in a new potent linear oxytocin antagonist Phaa-D -Tyr(Me)-Ile-Val-Asn-Orn-Pro-Orn-NH₂ (10). We report here the solid-phase synthesis of peptide 10 together with the following Tic-substituted peptides: 1, [Tic³]AVP; 2, d(CH₂)₅[D -Tic²]VAVP; 3, d(CH₂)₅[D -Tyr(Et)²Tic³]VAVP; 4, d(CH₂)₅[Tic²Ala-NH₂⁹]AVP; 5, d(CH₂)₅[Tyr(Me)², Tic³, Ala-NH₂⁹]AVP; 6, d(CH₂)₅ [Tyr(Me)², Tic⁷]AVP; 7, Phaa-D -Tyr(Me)-Phe-Gln-Asn-Lys-Tic-Arg-NH₂; 8, desGly-NH₂,d(CH₂)₅[Tic²,Thr⁴]OVT; 9, desGly-NH₂d(CH₂)₅[Tyr(Me)²Thr⁴, Tic⁷]OVT; 11, Phaa-D-Tic-Ile-Val-Asn-Orn-Pro-Orn-NH₂, using previously described methods. The protected precursors were synthesized by the solid-phase method, cleaved, purified and deblocked with sodium in liquid ammonia to give the free peptides 1–11 which were purified by methods previously described. Peptides 1–11 were examined for agonistic and antagonistic potency in oxytocic (in vitro, without Mg²⁺) and AVP antidiuretic (V₂-receptor) and vasopressor (V_1a-receptor) assays. Tic³ substitution in AVP led to drastic losses of V₂, V_1a and oxytocic agonistc activities in peptide 1.L - and D -Tic² substitutions led to drastic losses of anti-V₂/anti-V_1a and anti-oxytocic potencies in peptides 2, 4, 8 and 11 (peptide 2 retained substantial anti-oxytocic potency; pA₂ = 7.25 ± 0.25). Whereas Tic³ substitution in the selective V_1a antagonist d(CH₂)₅[Tyr(Me)², Ala-NH₂⁹]APV(C) led to a drastic reduction in anti-V_1a potency (from anti-V_1a pA₂) 8.75 to 6.37 for peptide 5, remarkably, Tic³ substitution in the V₂/V_1a antagonist d(CH₂)₅[D -Tyr(Et)²]VAVP(B) led to full retention of anti-V₂ potency and a 95% reduction in anti-V_1a potency. With an anti-V₂ pA₂ = 7.69 ± 0.05 and anti-V_1a pA₂ = 6.95 ± 0.03, d(CH₂)₅[D -Tyr(Et)²,Tic³]VAVP exhibits a 13-fold gain in anti-V₂/anti-V_1a selectivity compared to (B). Tic⁷ substitutions are very well tolerated in peptides 6, 7 and 9 with excellent retention of the characteristic potencies of the parent peptides. The findings on the effects of Tic³ substitutions reported here may provide promising leads to the design of more selective and possibly orally active V₂ antagonists for use as pharmacological tools and as therapeutic clinical agents for the treatment of the syndrome of the inappropriate secretion of antidiuretic hormone (SIADH).     

The nature of the requirement of Saccharomyces carlsbergensis for vitamin B6

Saccharomyces carlsbergensis 4228, an organism widely used for determination of vitamin B₆, grows well without this vitamin if thiamine is also omitted from the basal medium, and an inoculum grown in a thiamine-low medium is used. Thiamine inhibits growth when added to such a medium. The thiazole moiety of thiamine, but not the pyrimidine, is also inhibitory, but less so than thiamine itself.Growth inhibition by thiamine is prevented by vitamin B₆. At low concentrations of thiamine, the amount of vitamin B₆ required for growth increases with the thiamine concentration; at concentrations of thiamine above 1 μg./10 ml. the vitamin B₆ requirement for growth remains essentially constant. Since these higher concentrations of thiamine have been used in methods that utilize this organism for determination of vitamin B₆ (1,2), the validity of these methods is confirmed.In the presence of thiamine, growth was also permitted by additions of the thiamine antagonist, neopyrithiamine. In this case, however, the relationship was fully competitive; i.e., the amount of neopyrithiamine required for growth increased regularly with the thiamine concentration. At concentrations considerably higher than those required for growth, neopyrithiamine again inhibited growth, and this inhibition was prevented by an increase in the thiamine concentration. Thus neopyrithiamine acts by lowering the effective thiamine concentration to subinhibitory levels; if excessive amounts are used, it prevents essential metabolic functions of thiamine and itself becomes toxic. The mechanism by which vitamin B₆ prevents thiamine toxicity is not known.The appearance of a requirement for certain growth factors because of inhibitory effects of other metabolically important compounds, rather than because of an intrinsic inability of the organism to synthesize the growth factor, may be much more common than the few recorded instances of this phenomenon indicate.     

The possible role of intracellular receptors in the expression of narcotic antagonist precipitated abstinence

The antagonist potencies of methylnaloxone and naloxone were measured for morphine in the isolated guinea pig ileum by the pA₂ method and a potency ratio determined. A second potency ratio was determined by comparing the concentration of each antagonist required to produce abstinence-like contractures of ileal tissues from morphine-treated guinea pigs. If the latter response required penetration of the cell membrane lipid bilayer, one would expect methylnaloxone, a quaternary amine, to be significantly less potent than naloxone. Comparison of potency ratios for methylnaloxone and naloxone did not support this hypothesis.     

Evaluation of a novel aminopeptidase N inhibitor,in vitro,using two assay systems

The activities of the novel aminopeptidase N inhibitor (APNI), β-Amino-α-Hydroxyl-Phenyl butanic acid-Valine (AHPA-Val), were compared with APNI (amastatin). AHPA-Val and amastatin produced competitive inhibition of the hydrolysis of Tyr-Gly in the guinea-pig striatal membrane preparation, with K_i equal to 14.06 μM and 12.48 μM respectively. Met-enkephalin-induced twitch inhibition of the guinea-pig ileum preparation was enhanced by AHPA-Val and amastatin with pA_1/2 values (the negative logarithm concentration of APNI that decreased the IC₅₀ of Met-enkephalin by half), of 7.08 and 7.79 respectively. These results suggest that AHPA-Val has good activity as an APNI and that these two assay systems are useful for evaluating the potency of novel APNIs.     

Relationship between calcium release and NADPH oxidase inhibition in human neutrophils

The aim of this study was to investigate the possible relationship between NADPH oxidase activity and changes in cytosolic Ca²⁺ in response to different agonists. Treatment of neutrophils with leukotriene B4 (LTB₄) demonstrated characteristic changes to cytoslic Ca²⁺ yielding an EC₅₀ of 4 nM. The pA₂ values for the specific LTB₄ receptor (BLT) antagonists, U-75302 and LY-255283 were 6.32 and 6.38, respectively. Similarly, neutrophils treated with N-formyl-l-methionyl-l-leucyl-l-phenylalanine (FMLP) and platelet activating factor (PAF) exhibited changes in cytoslic Ca²⁺ in a dose dependant manner with pD₂ values of 9.0 and 9.9, respectively. The phorbol ester PMA prevented elevations in cytosolic Ca²⁺ in response to LTB₄, FMLP and PAF with IC₅₀ values of 5.88, 1.44 and 5.71 nM, respectively. In addition, potent NADPH oxidase inhibitors apocynin and diphenyleneiodonium (DPI) inhibited FMLP mediated cytosolic Ca²⁺ release. These results demonstrate that inhibition of the NADPH oxidase suppresses cytosolic Ca²⁺ release in FMLP activated human neutrophils.     

Search for multifunctional agents against Alzheimer’s disease among non-imidazole histamine H3 receptor ligands. In vitro and in vivo pharmacological evaluation and computational studies of piperazine derivatives

In the search for new treatments for complex disorders such as Alzheimer’s disease the Multi-Target-Directed Ligands represent a very promising approach. The aim of the present study was to identify multifunctional compounds among several series of non-imidazole histamine H3 receptor ligands, derivatives of 1-[2-thiazol-5-yl-(2-aminoethyl)]-4-n-propylpiperazine, 1-[2-thiazol-4-yl-(2-aminoethyl)]-4-n-propylpiperazine and 1-phenoxyalkyl-4-(amino)alkylopiperazine using in vitro and in vivo pharmacological evaluation and computational studies. Performed in vitro assays showed moderate potency of tested compounds against acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Molecular modeling studies have revealed possible interactions between the active compounds and both AChE and BuChE as well as the human H3 histamine receptor. Computational studies showed the high drug-likeness of selected compounds with very good physicochemical profiles. The parallel artificial membrane permeation assay proved outstanding blood–brain barrier penetration in test conditions. The most promising compound, A12, chemically methyl(4-phenylbutyl){2-[2-(4-propylpiperazin-1-yl)-1,3-thiazol-5-yl]ethyl}amine, possesses good balanced multifunctional profile with potency toward studied targets - H3 antagonist activity (pA₂ = 8.27), inhibitory activity against both AChE (IC₅₀ = 13.96 μM), and BuChE (IC₅₀ = 14.62 μM). The in vivo pharmacological studies revealed the anti-amnestic properties of compound A12 in the passive avoidance test on mice.